Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin In this edition Peter Goo
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin
In this edition Peter Goodwin and Sara Freeman report from:
European Breast Cancer Conference, Berlin, April 15-19, 2008;
Chemotherapy Foundation Symposium, November 6-10, 2007, New York;
9th European Congress: Perspectives in Lung Cancer, Turin, March 14-15, 2008;
The Lancet, New England Journal of Medicine
Myron Czuczman
In this edition:
1. Lymphoma Immunotherapy: Anti-CD-80 Therapy With Galiximab
Myron Czuczman, Roswell Park Cancer Institute, Buffalo NY
Chemotherapy Foundation
2. Esophagogastric Cancer: Capecitabine First Line?
George Canellos, Dana-Farber Cancer Institute, Boston
N Engl J Med 358:1
3. Mammography: As Good For Older Patients
Jacques Fracheboud, Erasmus Medical Center, Rotterdam
EBCC , Berlin
4. Mammography: Three Year Interval Justified
Roger Blamey, Nottingham City Hospital
5. Mammography Assessed
Michael Untch, HELIOS Klinikum, Berlin
6. Colorectal Cancer: Add Chemo To Liver Mets Resection?
George Canellos, Dana-Farber Cancer Institute, Boston
Lancet 371:1007
7. Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
Christian Manegold, Heidelberg University Medical Center, Manheim and Nick Thatcher, Christie Hospital, Manchester
European Lung Cancer Congress, Turin
8. Smoking And Death in India
George Canellos, Dana-Farber Cancer Institute, Boston
N Engl J Med 358:1137
Buy Audio Journal of Oncology Digital Copy
Order Audio Journal of Oncology CD
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/080515ajoiaVol16No10May15PODCAST.mp3]
Related Episodes
Fleur Mauritz MD; EBCC 2026: RAPCHEM Study Shows Risk-Based Radiotherapy De-Escalation is Safe After Primary Systemic Therapy for Early Breast Cancer
Fleur Mauritz MD discusses the 10-year follow-up findings from the RAPCHEM study, presented at the EBCC 2026. The research indicates that risk-based radiotherapy de-escalation is safe and effective following primary systemic therapy for early breast cancer patients. This approach allows for tailored treatment, potentially reducing side effects without compromising low recurrence rates. The study provides crucial long-term evidence supporting individualized radiotherapy strategies.
Jelle Wesseling MD PhD; 2026 EBCC: ‘Lord’ Trial Finds Active Surveillance for Estrogen-Receptor-Positive, HER2- Negative, Grade 1–2 DCIS Just As Effective as Standard Therapy
At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard therapy. The trial's reassuring findings led to early cessation of randomization, supporting de-escal
Elisa Agostinetto MD; 2026 EBCC: Circulating Tumor DNA Trumps Clinical Prognostic Markers After Neoadjuvant Therapy for Patients with Early Breast Cancer
Elisa Agostinetto MD presented at EBCC 2026, highlighting circulating tumor DNA (ctDNA) as a superior prognostic marker over clinical indicators for predicting relapse and progression in early breast cancer patients after neoadjuvant therapy. This research supports ctDNA for post-neoadjuvant risk st